** Shares of Optiscan Imaging rise 12.82% to A$0.22, on track for their best day since June 24, if gains hold
** The imaging technologies maker receives ethical clearance for breast cancer study
** Co says the study will assess the clinical workflow and real-time imaging capability of its recently unveiled InVue precision surgery imaging platform in breast cancer
** Stock has doubled gains this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((sherin.sunny@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments